Home » Stocks » Akouos

Akouos, Inc. (AKUS)

Stock Price: $24.33 USD 1.38 (6.01%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $24.01 -0.32 (-1.32%) Sep 25, 4:00 PM

Stock Price Chart

Key Info

Market Cap 836.24M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 34.37M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $24.33
Previous Close $22.95
Change ($) 1.38
Change (%) 6.01%
Day's Open 22.84
Day's Range 22.77 - 25.68
Day's Volume 274,166
52-Week Range 19.00 - 30.67

More Stats

Market Cap 836.24M
Enterprise Value 515.55M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.37M
Float 19.13M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 944,785
Short Ratio 9.22
Short % of Float 4.35%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.37
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 320.69M
Net Cash / Share 9.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(35.64% upside)
Current: $24.33
Target: 33.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-23.88-7.42
Net Income-25.74-6.01
Shares Outstanding0.610.47
Earnings Per Share-42.49-12.84
Operating Cash Flow-19.51-6.74
Capital Expenditures-3.44-0.53
Free Cash Flow-22.95-7.27
Cash & Equivalents26.4024.34
Total Debt13.78-
Net Cash / Debt12.6124.34
Book Value-32.80-7.23
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Akouos, Inc.
Country United States
Employees 54
CEO Emmanuel J. Simons

Stock Information

Ticker Symbol AKUS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AKUS
IPO Date June 26, 2020


Akouos, a precision genetic medicine company, develops gene therapies to restore, improve, and preserve physiologic hearing for people worldwide. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. Akouos has strategic partnerships with Massachusetts Eye and Ear and Lonza, Inc. The company was founded in 2016 and is headquartered in Boston, Massachusetts.